BTS 72664 是一种广谱、非镇静性、口服有效的抗惊厥剂,其抗惊厥作用主要源于增强 GABAA 受体 (GABAA receptor) 介导的氯通道电流,同时对 Na⁺ 通道 (Ki = 350 μM) 和 NMDA 受体 (NMDA receptor) (IC50 = 43 μM) 有弱阻断作用,可阻止神经元外谷氨酸、甘氨酸和丝氨酸浓度升高,减小脑梗死面积,促进功能恢复,预防多种类型癫痫发作,且镇静潜能较低,可用于癫痫、脑卒中及偏头痛的研究。
产品编号: MS-X68684 CAS No.: 165383-52-8 分子式: C13H11ClN4O 分子量: 274.71
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

BTS 72664 是一种广谱、非镇静性、口服有效的抗惊厥剂,其抗惊厥作用主要源于增强 GABAA 受体 (GABAA receptor) 介导的氯通道电流,同时对 Na⁺ 通道 (Ki = 350 μM) 和 NMDA 受体 (NMDA receptor) (IC50 = 43 μM) 有弱阻断作用,可阻止神经元外谷氨酸、甘氨酸和丝氨酸浓度升高,减小脑梗死面积,促进功能恢复,预防多种类型癫痫发作,且镇静潜能较低,可用于癫痫、脑卒中及偏头痛的研究。

生物实验数据

生物活性 BTS 72664 is a broad-spectrum, non-sedating, orally active anticonvulsant whose anticonvulsant effect primarily arises from enhancing GABAA receptor-mediated chloride channel currents, while weakly blocking Na⁺ channels (Ki = 350 μM) and NMDA receptors (IC50 = 43 μM); it prevents the elevation of extracellular neuronal glutamate, glycine, and serine concentrations, reduces cerebral infarct size, promotes functional recovery, prevents multiple types of seizures with low sedative potential, and can be used for research on epilepsy, stroke, and migraine.
体外研究
(In Vitro)

BTS 72664 (350 μM) 可弱结合于大鼠脑突触体膜中的电压门控 Na+通道,其 Ki 值为 350 μM。
BTS 72664 (300 μM; 0-6 seconds) 可使经去极化、Ca2+ 处理的大鼠脑突触体的 86Rb+ 外流显著降低 50%。
BTS 72664 可抑制 Veratridine (MS-A24312) 诱导的大鼠脑突触体谷氨酸外流,且不改变基础外流。
BTS 72664 (3-100 μM) 在大鼠大脑皮质脑片中可使 NMDA 诱导的去极化作用微弱降低约 20%,对非 NMDA 谷氨酸受体无显著活性。
BTS 72664 (0.3-300 μM) 可减弱大鼠脑皮质脑片的自发性癫痫样放电,其对 Bicuculline (MS-A54336) 诱导的 SED 的效力 (频率 IC50 为 94 μM) 强于对去除 Mg2+诱导的 SED 的效力 (频率 IC50 为 189 μM)。
BTS 72664 (100 μM; 20-45 min) 可使大鼠海马脑片 CA1 锥体神经元的静息膜电位超极化,平均超极化幅度为 9.5 mV。
BTS 72664 (10-100 μM) 可减弱培养的瑞士小鼠皮质神经元中 NMDA 诱发的电流,其 IC50 为 43 μM。
BTS 72664 (10-100 μM) 可通过不依赖苯二氮䓬、对 Picrotoxin (MS-F58453) 敏感的 GABAA 通道机制增强培养的瑞士小鼠皮质神经元中 GABA 诱发的电流,在 100 μM 时可产生 511% 的增强作用。

体内研究
(In Vivo)

BTS 72664 (1.9-9.4 mg/kg;口服;单次给药;每日一次;连续 5 天) 可强效保护小鼠对抗 Bicuculline 诱导的癫痫发作,其峰值效应下的口服 ED50 为 1.9 mg/kg,且连续 5 天每日给药未出现快速耐受现象。
BTS 72664 (47.5-77.2 mg/kg;口服;单次给药) 可预防小鼠中最大电休克诱导的癫痫发作,其口服给药达峰效应时的 ED50 为 47.5 mg/kg,作用时长为 4-6 hours,且在提高癫痫发作阈值方面的效力强于阻断癫痫发作泛化。
BTS 72664 (14 mg/kg;口服;单剂量) 可预防戊四氮诱导的小鼠癫痫发作,其口服 ED50 为 14 mg/kg,且在提高癫痫发作起始阈值方面具有极高的活性。
BTS 72664 (60 mg/kg;口服;单次给药) 可保护小鼠免受 Picrotoxin 诱导的癫痫发作,其口服 ED50 为 60 mg/kg。
BTS 72664 (25 mg/kg;口服;单次给药) 可预防小鼠由 4-aminopyridine (MS-S67830) 诱导的癫痫发作,其口服 ED50 为 25 mg/kg。
BTS 72664 (18 mg/kg;口服;单次给药) 可预防小鼠由 NMDA (MS-G13898) 诱导的癫痫发作,其口服 ED50 为 18 mg/kg。
BTS 72664 (9 mg/kg;口服;单次给药) 可对 DBA/2 小鼠的听源性癫痫发作起到保护作用,其口服 ED50 为 9 mg/kg。
BTS 72664 (29 mg/kg;口服;单次给药) 可对 GEPR-9 大鼠的癫痫发作起到保护作用,其口服 ED50 为 29 mg/kg。
BTS 72664 (4.6 mg/kg;口服;单次给药) 可预防 Bicuculline 诱导的大鼠癫痫发作,其口服 ED50 为 4.6 mg/kg,与小鼠相比效力的种属差异极小。
BTS 72664 (90 mg/kg;口服;单次给药) 可预防大鼠中最大电休克诱导的癫痫发作,其口服 ED50 为 90 mg/kg,与小鼠相比效力的物种差异极小。
BTS 72664 (100-150 mg/kg;口服;单次给药) 可剂量依赖性地改善杏仁核点燃大鼠的癫痫发作参数,其中 150 mg/kg 口服剂量可使癫痫发作阈值升高 177%,癫痫发作持续时间缩短 65%。
BTS 72664 (50 mg/kg;口服;每 12 小时 1 次;共给药 4 次),可使永久性大脑中动脉闭塞的褐家鼠的缺血性病灶体积减少 31%,并促进其功能恢复1]。
BTS 72664 (20-35 mg/kg;腹腔注射;初始单次给药;每 12 小时 1 次;后续给药 3 次),于栓塞后 60 分钟开始给药,可使永久性大脑中动脉栓塞大鼠的缺血病灶体积减少 40%,且该神经保护作用无低温因素参与。
BTS 72664 (50 mg/kg;口服;单次给药),于大鼠皮层损伤后 15 分钟给药,可快速且持续地消除皮层扩散性抑制相关的大鼠细胞外谷氨酸、甘氨酸和丝氨酸水平升高。

Animal Model: Swiss CD1 mice
Dosage: 1.9 mg/kg (30 min post-dose); 9.4 mg/kg (60 min post-dose); 2.8 mg/kg (chronic)
Administration: p.o.; single dose; p.o.; daily; 5 days
Result: Had an ED50 of 1.9 mg/kg p.o.
for protection against bicuculline-induced seizures at 30 min post-dose.
Had an ED50 of 9.4 mg/kg p.o.
for protection against bicuculline-induced seizures at 60 min post-dose.
Showed no significant attenuation of anticonvulsant efficacy after 5 consecutive days of 2.8 mg/kg p.o.
daily dosing compared to a single dose.
Animal Model: Swiss CD1 mice
Dosage: 47.5 mg/kg (30 min post-dose); 77 mg/kg (60 min post-dose); 77.2 mg/kg (peak protection)
Administration: p.o.; single dose
Result: Had an ED50 of 47.5 mg/kg p.o.
for protection against maximal electroshock-induced seizures at 30 min post-dose.
Had an ED50 of 77 mg/kg p.o.
for protection against maximal electroshock-induced seizures at 60 min post-dose.
Provided peak protection against maximal electroshock-induced seizures at 30 min post-dose with a duration of action of 4-6 hours at 77.2 mg/kg p.o.
Had a TID20 of 5.7 mg/kg p.o.
for increasing seizure current threshold by 20%.
Animal Model: Swiss CD1 mice
Dosage: 14 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 14 mg/kg p.o.
for protection against subcutaneous pentylenetetrazol-induced seizures.
Had a TID20 of 5.6 mg/kg p.o.
for increasing pentylenetetrazol-induced initial myoclonic twitch threshold by 20%.
Had a TID20 of 1.1 mg/kg p.o.
for increasing pentylenetetrazol-induced generalized clonic seizure threshold by 20%.
Animal Model: Swiss CD1 mice
Dosage: 60 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 60 mg/kg p.o.
for protection against subcutaneous picrotoxin-induced seizures.
Animal Model: Swiss CD1 mice
Dosage: 25 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 25 mg/kg p.o.
for protection against intracerebroventricular 4-aminopyridine-induced seizures.
Animal Model: Swiss CD1 mice
Dosage: 18 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 18 mg/kg p.o.
for protection against intracerebroventricular NMDA-induced seizures.
Animal Model: DBA/2 mice
Dosage: 9 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 9 mg/kg p.o.
for protection against audiogenic seizures in DBA/2 mice.
Animal Model: GEPR-9 rats
Dosage: 29 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 29 mg/kg p.o.
for protection against seizures in GEPR-9 rats.
Animal Model: Rats
Dosage: 4.6 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 4.6 mg/kg p.o.
for protection against bicuculline-induced seizures in rats.
Animal Model: Rats
Dosage: 90 mg/kg
Administration: p.o.; single dose
Result: Had an ED50 of 90 mg/kg p.o.
for protection against maximal electroshock-induced seizures in rats.
Animal Model: Rats
Dosage: 100 mg/kg; 150 mg/kg
Administration: p.o.; single dose
Result: Increased mean kindled seizure threshold by 68% at 100 mg/kg p.o.
Increased mean kindled seizure threshold by 177% at 150 mg/kg p.o.
Reduced mean seizure severity by 59% at 150 mg/kg p.o.
Reduced mean seizure duration by 65% (from 69 to 24 sec) at 150 mg/kg p.o.
Reduced mean afterdischarge duration by 68% (from 105 to 34 sec) at 150 mg/kg p.o.
Caused mild ataxia at 150 mg/kg p.o.
but no significant motor impairment in the rotarod test.
Animal Model: Rats
Dosage: 50 mg/kg
Administration: p.o.; every 12 hours; 4 total doses
Result: Reduced cerebral lesion volume by 31% (treated: 56.9 mm3; vehicle: 82.6 mm3) at 2 days post-insult.
Showed a significant reduction in contralateral forelimb faults on day 8 post-insult, and when data from days 3, 6, and 8 were combined, compared to vehicle-treated controls.
Animal Model: Rats
Dosage: 20 mg/kg (subsequent doses); 35 mg/kg (initial dose)
Administration: i.p.; single initial dose; i.p.; every 12 hours; 3 subsequent doses
Result: Reduced cerebral lesion volume by 40% (treated: 43.6 mm3; vehicle: 72.0 mm3) at 6 days post-insult.
Did not decrease core body temperature when monitored for 18 hours after the initial 35 mg/kg i.p.
dose.
Animal Model: Rats
Dosage: 50 mg/kg
Administration: p.o.; single dose
Result: Abolished the transient, insult-induced increases in extracellular glutamate, glycine, and serine levels in the parietal cortex.
Did not alter extracellular GABA levels, but reduced extracellular glutamate levels compared to basal values in anesthetic-only controls.
Exhibited a rapid onset (30 min post-administration) and effect lasting for at least 2.25 hours from peak brain levels.

化学信息

分子量 274.71
分子式 C13H11ClN4O
CAS No. 165383-52-8

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础